Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Biopharm Knowledge Publishing

Outlook 2009 - Global Pharmaceutical and Biotechnology Markets

Pharmaceutical Market Trends, 2008 - 2012: key market forecasts & growth opportunities
The latest version of this best-selling report presents a detailed trend analysis of the global pharmaceutical market to the end of 2007 and forecasts until 2012. The 142 page report presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

Quality for Biologics
Biologic drugs are complicated biological products that are normally difficult to define in molecular terms and that can be inconsistent in their exact composition. This can make it difficult to assure product quality and therefore to ensure safety and efficacy. There is no perfect solution and the commercial cost of quality is high, but the cost of getting it wrong can be considerably greater or even disastrous. Considerable time and expense can be saved by having an educated approach to manufacturing and process development, characterisation and analytical methods, product variation and also to regulatory issues. This unique new report provides a detailed and complete guide to the processes and methods involved.

Virtual Pharma - the radical route to success
Mega mergers and the blockbuster model have not delivered the benefits that were claimed for them - growth in the pharmaceutical market has slowed to no more than five per cent and the world's biggest companies are growing slowly, if at all. Against that background pharmaceutical companies, large and small, are looking for new ways to do business - ways that will bring success in a difficult market. For ways to discover and deliver new drugs, to manufacture them more cost-effectively and to sell and market them more successfully.

EvaluatePharma® Yearbook Company Performance Tables
In a fast-changing pharmaceutical market it is vital to be able to measure company performance easily and accurately - find out which companies are winning in the areas that count and which are suffering in changing circumstances. The new EvaluatePharma® Yearbook gives you the information that you need, in context.

The Rise of Mid-Sized Pharma
What makes mid-sized companies successful – and what big Pharma can learn from them

Since the year 2000 mid-sized pharmaceutical companies have out performed their larger rivals – they have grown more rapidly, produced better profits and have performed far better on the world’s stock markets.

There are many reasons why this has happened; big pharma is facing a multitude of serious problems that it did not realise were important just a few years ago. Now there are major issues with public perception, an innovation deficit and increased regulation.

Contract Research Annual Review 2008
The contract research market is booming, growing by 28% last year - far faster than the industry it serves. This review provides a complete picture of the market, looks at trends and developments and explains how they will affect the future of the market. And it includes details of more than 50 mergers, acquisitions and joint ventures.

Cardiac Toxicity
Cardiac Toxicity – drugs causing heart muscle, valve damage or potentially fatal arrhythmias in patients - has been implicated in 28% of drug withdrawals in the USA over the last 30 years.

The significance for patients, regulators and the pharmaceutical industry is immense. If cardiac toxicity is discovered during a drug’s development the programme will, almost invariably, be terminated. If cardiac toxicity is discovered after launch then the drug may be withdrawn or new labelling will almost certainly be required.

Biopharm Outsourcing Register
The Biopharm Outsourcing Register provides a fast, efficient, user-friendly solution to searching for a service organisation direct from your own desktop.

Subscribers can search by single or multiple parameters to target quickly those companies best able to meet a specific outsourcing need.

The Biopharm Outsourcing Register contains details of 1,400 organisations - the most comprehensive global database available:

* Global CROs - Clinical Research, Data Management & Regulatory Affairs

* Global CROs - Preclinical, Toxicology & Analysis

* Global CMOs - Manufacturing Services

Immunogenicity to Biologics Implications of reactions against biotech drugs
Understanding immunogenicity, a detrimental and potentially dangerous response to therapeutic proteins, is vitally important for the successful development and marketing of biotech drugs. Failure to predict and minimise levels of immunogenicity may have harmful and sometimes disastrous results for both patients and the industry.

Central and Core Laboratories
A definitive report on the current status and future prospects of Central Clinical Pathology Laboratories, Central ECG Analysis Laboratories and Central Bio-imaging Laboratories.

Biosimilars - Evolution or Revolution?
A detailed guide to the factors that will shape this vital market, including company strategies, comparability, regulation, the implications for clinical trials and legal issues. With a chapter written by PricewaterhouseCoopers looking at the commercial implications for the biotech and pharmaceutical markets

Outsourcing Chemistry Services Made Easy
Pharmaceutical and biotech companies are outsourcing more of their work than ever before – the list includes drug discovery, development, manufacture and marketing.

This new report provides a clear, comprehensive guide to the processes involved in outsourcing chemical and biotech development and production.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions